PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is the phase IV, open-label, clinical trial to determine the efficacy of niraparib
maintenance therapy in BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer
patients.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Asan Medical Center Samsung Medical Center Takeda Yonsei University